SCHEDULE 13G/A: Samlyn Capital, LP, and Robert Pohly Report Zero Beneficial Ownership in Inozyme Pharma, Inc.
Ownership Disclosure Amendment
Samlyn Capital, LLC, Samlyn, LP, and Robert Pohly have filed an amended Schedule 13G, indicating they no longer beneficially own any shares of Inozyme Pharma, Inc. as of December 31, 2024.
Summary
- Samlyn Capital, LLC, Samlyn, LP, and Robert Pohly have filed an Amendment No. 1 to Schedule 13G regarding their holdings in Inozyme Pharma, Inc.
- As of December 31, 2024, all reporting persons, including Samlyn Capital, LLC, Samlyn, LP, and Robert Pohly, beneficially own 0 shares of Inozyme Pharma, Inc. Common Stock.
- This represents 0% of the outstanding Common Stock of Inozyme Pharma, Inc.
- The filing states that the securities were acquired and held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
- All securities reported are directly owned by advisory clients of Samlyn Capital, LLC, none of whom beneficially own more than 5% of the Common Stock.
Sentiment
Score: 5
Explanation: The document is a neutral, factual regulatory filing disclosing a change in beneficial ownership to zero. It contains no positive or negative statements about the issuer's performance or prospects.
Future Outlook
NA
Industry Context
This filing is a standard regulatory disclosure of an institutional investor's reduced or terminated stake in a public company. It does not provide information on broader industry trends or competitive landscape.
Stakeholder Impact
- Shareholders: Existing shareholders may note the exit of Samlyn Capital, LLC, Samlyn, LP, and Robert Pohly as beneficial owners, which could be interpreted as a lack of continued conviction by these investors. The impact depends on the size of their previous holding.
- Employees, Customers, Suppliers, Creditors: No direct impact is indicated by this ownership disclosure.
Key Dates
| Date | Description |
|---|---|
| 12/31/2024 | Date of event requiring the filing of this statement, indicating the reporting persons no longer hold a reportable beneficial ownership stake. |
| 02/14/2025 | Date of filing of the Schedule 13G Amendment No. 1. |
Keywords
Inozyme Pharma, Samlyn Capital, Samlyn LP, Robert Pohly, Schedule 13G, Ownership Disclosure, Common Stock, Beneficial Ownership, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.